NCT04114994

Brief Summary

The Boston Cognitive Assessment (BoCA) is a self-administered online test intended for longitudinal cognitive monitoring. BoCA uses random not-repeating tasks to minimize learning effects. BoCA was developed to evaluate the effects of treatment in longitudinal clinical trials and available gratis to individuals and professionals.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10,000

participants targeted

Target at P75+ for all trials

Timeline
42mo left

Started Oct 2019

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress66%
Oct 2019Oct 2029

Study Start

First participant enrolled

October 1, 2019

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

October 2, 2019

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 3, 2019

Completed
10 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2029

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2029

Last Updated

August 1, 2024

Status Verified

July 1, 2024

Enrollment Period

10 years

First QC Date

October 2, 2019

Last Update Submit

July 31, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Boston Cognitive Assessment (BoCA)

    The Boston Cognitive Assessment (BoCA) is a self-administered online test intended for longitudinal cognitive monitoring. BoCA uses random not-repeating tasks to minimize learning effects. BoCA was developed to evaluate the effects of treatment in longitudinal clinical trials and available gratis to individuals and professionals.

    through study completion, an average of 1 year

Study Arms (8)

Alzheimer's Disease

Diagnostic Test: Boston Cognitive Assessment (BoCA)

Mild Cognitive Impairment

Diagnostic Test: Boston Cognitive Assessment (BoCA)

Frontotemporal Dementia

Diagnostic Test: Boston Cognitive Assessment (BoCA)

Vascular Dementia

Diagnostic Test: Boston Cognitive Assessment (BoCA)

Parkinson Disease

Diagnostic Test: Boston Cognitive Assessment (BoCA)

Traumatic Brain Injury (TBI)

Diagnostic Test: Boston Cognitive Assessment (BoCA)

Multiple Sclerosis

Diagnostic Test: Boston Cognitive Assessment (BoCA)

No diagnosis

Diagnostic Test: Boston Cognitive Assessment (BoCA)

Interventions

The Boston Cognitive Assessment (BoCA) is a self-administered online test intended for longitudinal cognitive monitoring. BoCA uses random not-repeating tasks to minimize learning effects. BoCA was developed to evaluate the effects of treatment in longitudinal clinical trials and available gratis to individuals and professionals. BoCA includes eight subtests in the following domains: Memory/Immediate Recall, Memory/Delayed Recall, Executive function/ Visuospatial, Executive function/ Mental rotation, Attention, Mental math, Language/Prefrontal Synthesis, and Orientation. The maximum total score is 30. Higher score indicates better cognitive performance. After BoCA is completed, the domain scores and total score are provided immediately. Users will also receive an email with the link to the full report with progress charts.

Alzheimer's DiseaseFrontotemporal DementiaMild Cognitive ImpairmentMultiple SclerosisNo diagnosisParkinson DiseaseTraumatic Brain Injury (TBI)Vascular Dementia

Eligibility Criteria

Age50 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

According to the American Academy of Neurology, nearly 7% of people in their early 60s worldwide have mild cognitive impairment, while the condition affects 38% of people ages 85 and older. The BoCA evaluation can help doctors figure out if an underlying condition is causing a patient's cognitive decline. Many treatable conditions such as sleep disorders, mood problems, heavy metal accumulation, as well as lack of movement and social interactions can affect memory and thinking. Our goal is to reduce barriers for patients to receive the testing that may benefit their treatment and health through the use of digital technology.

You may qualify if:

  • age 50 or older

You may not qualify if:

  • younger than 50 years

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Andrey Vyshedskiy

Miami, Florida, 33156, United States

RECRUITING

Related Publications (1)

  • Foster NL, Bondi MW, Das R, Foss M, Hershey LA, Koh S, Logan R, Poole C, Shega JW, Sood A, Thothala N, Wicklund M, Yu M, Bennett A, Wang D. Quality improvement in neurology: Mild cognitive impairment quality measurement set. Neurology. 2019 Oct 15;93(16):705-713. doi: 10.1212/WNL.0000000000008259. Epub 2019 Sep 18. No abstract available.

    PMID: 31534026BACKGROUND

Related Links

MeSH Terms

Conditions

Alzheimer DiseaseCognitive DysfunctionDementia, VascularFrontotemporal DementiaParkinson DiseaseMultiple Sclerosis

Condition Hierarchy (Ancestors)

DementiaBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersMental DisordersCognition DisordersCerebrovascular DisordersIntracranial ArteriosclerosisIntracranial Arterial DiseasesLeukoencephalopathiesArteriosclerosisArterial Occlusive DiseasesVascular DiseasesCardiovascular DiseasesFrontotemporal Lobar DegenerationTDP-43 ProteinopathiesProteostasis DeficienciesMetabolic DiseasesNutritional and Metabolic DiseasesParkinsonian DisordersBasal Ganglia DiseasesMovement DisordersSynucleinopathiesDemyelinating Autoimmune Diseases, CNSAutoimmune Diseases of the Nervous SystemDemyelinating DiseasesAutoimmune DiseasesImmune System Diseases

Central Study Contacts

ANDREY VYSHEDSKIY, Ph.D.

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 2, 2019

First Posted

October 3, 2019

Study Start

October 1, 2019

Primary Completion (Estimated)

October 1, 2029

Study Completion (Estimated)

October 1, 2029

Last Updated

August 1, 2024

Record last verified: 2024-07

Locations